The Canadian National Breast Screening Study (CNBSS), conducted on women age 40-49, was designed to evaluate the efficacy of combined annual mammography and physical examination of the breasts in reducing breast cancer mortality in comparison to usual care (UC) controls. From January 1980 through March 1985, 25,214 women were individually randomized to the mammography/physical exam (MP) arm and 25,216 to the UC. The integrity of the randomization has been reviewed and confirmed to be unbiased. During an average follow-up of 10.5 years from entry (range: 8.75-13 years), 82 women died from breast cancer in the MP arm and 72 in the UC, for a rate ratio of 1.14 (95% confidence interval: 0.83-1.56). All-cause mortality was almost identical comparing the two groups; the nonsignificant excess of breast cancer deaths in the MP arm was balanced by an excess of other cancer deaths in the UC arm. [Monogr Natl Cancer Inst 1997:22:37-41]
The Canadian National Breast Screening Study (CNBSS) is an individually randomized trial designed to evaluate, in women age 40-49 on entry to the study, the combined efficacy of annual mammography, physical examination of the breasts, and the teaching of breast self-examination in reducing breast cancer mortality (1) . Thus, it was specifically designed to evaluate the efficacy of screening in women who chose to be screened, rather than evaluating the effectiveness of screening in the population. Efficacy trials are usually regarded as necessary before effectiveness (population-based) trials are conducted. To date, it is the only trial specifically designed to evaluate screening in women age 40-49, rather than in a wider age range, that has reported upon breast cancer mortality.
In our published seven-year mortality report (2), we demonstrated that the two arms of the study were well balanced with respect to age, marital status, number of live births, menopausal status, education, family history of breast cancer, and place of birth. The validity of the randomization has since been challenged (3) . More women with breast cancer with four or more nodes were identified at the initial screening examination in the treatment, or mammography/physical exam (MP) arm, than in the usual care (UC) control arm. However, Bailar and MacMahon (4) carried out an independent review of randomization for the National Cancer Institute of Canada, paying particular attention to the centers where the excess was concentrated, and they found no evidence of any deliberate falsification of randomization such that more women with ''advanced'' breast cancers were placed in the MP arm. Further, an independent validation of CNBSS data from the Manitoba screening center has found no evidence of falsification there either (5) . A commentary by Boyd (6) attempted to cast some doubt on whether, ''the debate is over.'' Accordingly, we shall try to put the record straight in what follows.
The other issue that has surfaced relates to mammography quality (7) (8) (9) . Several procedures were put in place in the CNBSS to obtain high-quality mammography. Centers with mammography experience were selected, dedicated mammography machines and film processing were required, modern filmscreen technology was used, there was extensive reference physicist (10) and reference radiologist (11, 12) monitoring, external reviews of mammography were conducted (13, 14) , and the findings were reported back to the study centers. Our procedures were designed to maximize the sensitivity of the screen, even at the cost of reduced specificity. As Fletcher et al. (15) have reported, these efforts resulted in parameters of quality that rivaled all other screening trials in this age group. As a result, the sensitivity of the screen in the MP arm was 81%, the first round breast cancer detection rate was 3.9 per 1,000, the prevalence/ incidence ratio was 2.7, and 65% of the invasive screen-detected breast cancers were node negative.
Methods
Women with no previous history of breast cancer and no mammogram in the previous 12 months were eligible for the trial, providing they signed an informed consent form. A total of 50,430 women age 40-49 were enrolled from January 1980 through March 1985 from 15 centers across Canada. Randomization was to mammography and physical examination of the breasts (the MP allocation) or to a control group receiving usual care in the context of the Canadian health care system (the UC allocation). Randomization was performed by the local coordinators by reference to prearranged lists, after the coordinators had received from the examiner the signed informed consent and completed initial physical examination forms. This was to ensure that the physical examination would be conducted and the findings recorded without knowledge as to whether mammography was allocated. In the MP allocation, five annual screens were offered to the majority of participants; those enrolled in the last year of recruitment in the individual centers were only offered four annual screens. The participants in the UC arm received annual questionnaires over the same time period. Com-pliance with rescreening and with returning questionnaires was excellent, exceeding 90% in both arms. Breast cancer mortality has been ascertained by annual follow-up of all women known to have been diagnosed with breast cancer, and by linking CNBSS records to the Canadian National Mortality Data Base (CNMDB), initially for deaths up to December 31, 1988, and more recently to December 31, 1993, the closing date for the present analysis. Thus, participants have been followed for a mean of 10.5 years, with a range of 8.75 to 13 years.
The trial was planned with sufficient power to detect a 40% reduction in breast cancer mortality at five years from entry (1). However, because insufficient deaths from breast cancer had occurred by five years to attain the planned power, the follow-up was extended for two years, by which time there were enough breast cancer deaths to reach the planned power (2) . The present report provides the findings from an additional three years of follow-up, providing sufficient power to detect at least a 30% reduction in breast cancer mortality.
Results
If women had been deliberately placed in the MP arm because of concern over their possible risk of breast cancer-due to, say, a strong family history of breast cancer-an excess of women with risk factors would have been detected in the MP arm. As shown in Table 1 , that was not so. If, on the other hand, the concern was that the woman already had signs or symptoms of breast cancer, the examiner would have identified an abnormality. However, all women with clinically detected abnormalities were referred to the CNBSS review clinic to be assessed by the study surgeon. Table 2 demonstrates that such referrals were similar across the two arms within the study centers. Other analyses have shown women who reported breast symptomatology at the time of their initial physical examination were equally distributed.
Using the data from the CNMDB to December 31, 1993, we identified 82 breast cancer deaths in the MP arm and 72 in the UC arm. In terms of person-years of observation to December 31, 1993, this is a rate ratio of 1.14 (95% confidence interval [CI]: 0.83-1.56). The cumulative mortality from breast cancer over the 13 years of observation is presented in Figure 1 .
The distribution of breast cancer deaths in relation to various factors is presented in Table 3 . Although there are some inequalities by five-year age groups, the differences are not statistically significant. Less than half the breast cancer deaths in both arms were among women referred to review after the first screen. Again, there are no differences between the arms. We have noted elsewhere that the detection of an abnormality on physical examination was a risk factor for subsequent breast cancer detection, as it was for mammography (16) . A minority of breast cancer deaths were among women with breast cancers detected at the first screen. There were more in the MP than the UC arm, as a result of the additional cancers found by mammography. When all breast cancer deaths were related to nodal status at the time of diagnosis of the cancer, we found a higher proportion of deaths among women with cancers labeled as node negative in the UC arm. Table 4 shows the distribution of deaths from all causes up to December 31, 1993. Although breast cancer was the largest single cause of death, it accounted for only 19.6 % of the deaths in the MP arm and 17.4% in the UC. There are minor differences in some categories, but in general, the reported causes of death were remarkably similar, thus providing further confirmation that the randomization resulted in comparable groups.
Discussion
The present report more than doubles the number of breast cancer deaths previously noted at seven years. In the seven-year report (2) , there were 38 deaths from breast cancer in the MP and 28 in the UC allocation. The ratio of the proportions of breast cancer deaths in the MP allocation compared to the UC was 1.36 (95% CI: 0.84-2.21). Breast cancer mortality figures derived from our routine annual follow-up of all the breast cancers ascertained in the study were included in the summary report from the March 1996 meeting in Falun, Sweden, resulting in 78 in the MP arm and 73 in the UC (17) . Currently, at a mean follow-up time of 10.5 years, we are able to exclude, with 95% confidence, a reduction of breast cancer mortality of 17% or more. Although the absolute level of the nonsignificant excess of breast cancer mortality found previously in the MP arm has not changed comparing seven year to current results, proportionately it is now much less.
Having failed to find a benefit from screening in women who initiate screening at ages 40-49, the CNBSS has been subjected to intense review and criticism. Similar scrutiny has not been applied to trials that did report a benefit. For example, in his comments on the meta-analysis by Smart et al. (18) , Boyd (6) fails to note that the trials, other than HIP, that contributed to the suggestion ''that mammography is effective in reducing the rate of death from breast cancer in this age group'' (18) have not published data confirming equivalence of subjects in the compared arms at the time of randomization, as has the CNBSS. Indeed, many are cluster-randomized trials, and differences between the clusters are to be expected; yet, the design effect of the cluster randomization has not been factored into the metaanalysis, so that the confidence intervals reported are too narrow.
A great deal of attention has also been given to the excess of breast cancers with four or more positive nodes in the first screen in the MP arm compared to the UC in the CNBSS (3, 6) . Variables that become apparent as a result of screening and diagnosis have been called pseudo-variables by Prorok et al. (19) and are biased. Nodal status is one such variable. Whether the CNBSS study surgeon referred a woman with a physical ''abnormality'' for subsequent diagnosis (and biopsy) in the community was influenced by the availability of mammograms in the MP group and their nonavailability in the UC group. Several women with four or more nodes were probably unrecognized in the UC group, and many were not even recognized as node positive subsequently, as they were more likely to be treated in centers where careful extensive nodal dissection or evaluation by skilled pathologists was not the norm. Some may not have had nodal dissection at all. Moreover, in the MP arm, many of the so-called ''advanced'' cancers were small, with limited involvement of the individual nodes, and were thus not clinically advanced, even though four or more nodes were found to be involved after careful dissection and histologic sectioning.
The higher proportion of breast cancer deaths among nodenegative women in the UC arm is further evidence that the difference in nodal status between the MP and UC groups detected at initial screening was partly due to failure to identify as node positive a number of the breast cancers in the UC arm. That the initial excess of four or more node positive cancers in the MP arm is due to a diagnostic bias is confirmed by the similarity in numbers of breast cancer deaths among women with cancers ascertained either by screening or as interval cancers in the first 12 months after entry (see Baines, this volume). An explanation for the persistent excess of 10 breast cancer deaths in the MP arm may be found in Table 4 , which shows a deficit of colorectal and stomach cancer deaths. It seems possible that this is an example of the ''sticking diagnosis'' phenomenon. Women diagnosed with breast cancer as a result of mammography screening, and who developed metastatic disease, may be less likely to be investigated for a new primary tumor than women without a breast cancer diagnosis in the UC arm. Thus, it is possible that some of the breast cancer deaths in the MP arm were in fact due to a second primary in the gastrointestinal tract.
The initial physical examinations in the CNBSS have been referred to as a ''prescreen'' by some commentators. That is incorrect. The physical examinations were administered as screening tests that were evaluated and subject to quality control in the same way as mammography. Both groups were initially screened by physical examination, an approach in the UC group that mimics what a careful physician might be expected to perform on women in this age group in North America before deciding whether to prescribe mammography. About a quarter of the women in the UC arm received one or more mammograms during the course of the trial, as was expected from the ready availability of mammography in the Canadian health care system. That was not ''contamination''; it was good usual care. We have demonstrated that substituting annual mammography and physical examinations for such usual care during a four-year period has no impact on breast cancer mortality over a 8.75-to 13-year period. ''Modern'' mammography is said to be much improved compared to CNBSS mammography. But what is the nature of the improvement? Few data have been presented that support increased sensitivity from the mammography of the 1990s compared to that of the 1980s. Rather, what has happened is a major improvement in specificity, reducing anxiety in screened women and health care costs, but having no impact upon breast cancer mortality.
Boyd (6) and others have commented that longer follow-up of the existing trials over the next few years ''should settle the debate.'' This seems unlikely, given the lack of any indication of benefit with longer follow-up in the CNBSS. Further, the lead time gained by the MP screen in the CNBSS in women age 40-49 was 2.3 years (95% CI: 1.5-3.2) compared to 3.6 years (95% CI: 2.7-5.5) for women age 50-59 (To T, Miller AB, Xie HX, Walter S., ''Lead time estimation and its use in survival analyses as applied to the National Breast Screening Study,'' submitted, 1997). This supports other studies that suggest that the rate of progression of breast cancer in premenopausal women is faster than in postmenopausal women (17) . This makes it unlikely that a delayed benefit of breast cancer screening in younger compared to older women explains the trends seen after 10 years in some studies of the long-term follow-up of women screened initially under and over the age of 50 (20) , in spite of attempts to provide a rationale for this paradoxical finding (17) .
One reason for the CNBSS not showing a breast cancer mortality reduction (even though some other trials have suggested a benefit beginning after seven years from entry) may be the smaller size of the tumors in the control arm of the CNBSS compared to control women in the Swedish Two-County Trial (Narod S, ''On being the right size: a reappraisal of mammography trials in Canada and Sweden,'' submitted, 1997). This would explain the superior survival of UC women with breast cancer at seven years (2) compared to those in the Swedish Two-County Trial (21) . Further, there was almost universal use of adjuvant chemotherapy for node-positive breast cancer in Canada during the 1980s, whereas adjuvant chemotherapy was not used in the trials in Sweden that began in the 1970s (Tabar, L, personal communication, 1997) . It has been suggested, on the basis of the Two-County Trial, that only a limited proportion of breast cancers can benefit from early detection from screening (17) . If this segment is benefited by usual care in the Canadian health care context, or is the same as can be cured by adjuvant chemotherapy, it is scarcely surprising that screening cannot be shown to make an additional impact.
In the light of our results, what should women be advised? It seems important that women should understand that the largest trial to date shows no evidence of benefit from initiating mammography screening under the age of 50. This negative finding, however, must be placed in the context that the CNBSS is the only trial since HIP designed specifically to evaluate screening in North America. Still, even two-view mammography, conducted annually, has not resulted in the earlier detection of curable cancers which would be fatal in the absence of their early detection. Thus, although women may choose to be screened by mammography, they should understand that usual care, as defined in Canada with the ready availability of physical examinations of the breasts, the practice of breast self-examination, diagnostic mammography, and good cancer treatment, seems an extremely viable option.
In closing, we emphasize that this is a preliminary update from our recent linkage between the CNBSS file and the Canadian National Mortality Data Base. There will probably be some minor changes in the numbers reported in this paper, as the breast cancer deaths now known to us are not the final tally for the 10-to 15-year report currently in preparation. Only when we are able to evaluate the findings from the record linkage to the Canadian National Cancer Registry, currently underway, will we be able to produce the final tally. Nevertheless, it seems unlikely that our present findings will change to any great degree.
Conclusion
The CNBSS is internally valid and there is no evidence of bias in allocation. Screening of women age 40-49 with yearly mammography and physical examination has had no impact on mortality from breast cancer during 8.75 to 13 years from entry.
